Purchase this article with an account.
Ronald V Krüger, Daniela Claessens; Metamorphopsia measurement with AMD - A Metamorphopsia Detector® as a patient reported outcome (PRO) measure. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1522.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Metamorphopsia as a patient reported outcome can be documented by the computer based interactive program AMD - A Metamorphopsia Detector® (patent pending). This study was performed to compare metamorphopsia measurement by AMD - A Metamorphopsia Detector® with results of the National Eye Institute Visual Function Questionnaire- 25 (NEI-VFQ 25) reflecting vision related quality of life.
75 patients with unilateral metamorphopsia performed monocular metamorphopsia measurement with AMD – A Metamorphopsia Detector®. The software uses the concept of a negative image: a distorted image can be straightened by moving the mouse. Amplitude, localization and area of distorted lines are transformed into single dimensions and summarized in a global value. All patients were asked to fill out the NEI-VFQ 25: response rate was 56% (n=42, caucasian, age 40-86 years, 19 male, 23 female). In all responding patients (macular edema due to age related macular degeneration=22, central venous thrombosis=2, diabetes=3, uveitis=4, intermediate AMD=7, macular pucker=4) correlation of NEI-VFQ 25 (subscale near vision) on the one side and global value / single dimensions of Metamorphopsia measurement with AMD - A Metamorphopsia Detector® as a patient reported outcome were measured. Visual acuity of the partner eye was taken into account as a potential confounder. Prior to the study all patients signed informed consent according to the declaration of Helsinki/Edinburgh.
Correlation of metamorphopsia global value with subscale near vision of NEI VFQ 25 was very high: Pearson correlation coefficient ρ = -0,87 (95% confidence interval: -0.93;-0.77, p < 0.001).Correlation of metamorphopsia single dimensions with NEI VFQ 25 was very high: ρ = -0.85 (CI: -0.92;-0.74, p < 0.001) / ρ = -0,82 (CI: -0.9;-0.7, p < 0.001) / ρ = -0.71 (CI: -0.86;-0.57, p < 0.001) for amplitude, localization and area of distortion.
As a quantitative test highly correlating with vision related quality of life AMD – A Metamorphopsia Detector® can deliver information about a patient reported outcome in macular disease.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only